• H. M. Shepard
  • P. Jin
  • D. J. Slamon
  • Z. Pirot
  • D. C. Maneval
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 181)

The biology of the human epidermal growth factor (EGF) receptor-2 (HER2) has been reviewed numerous times and provides an excellent example for developing a targeted cancer therapeutic. Herceptin, the FDA-approved therapeutic monoclonal antibody against HER2, has been used to treat over 150,000 women with breast cancer. However, the developmental history of Herceptin, the key events within the program that created pivotal decision points, and the reasons why decisions were made to pursue the monoclonal antibody approach have never been adequately described. The history of Herceptin is reviewed in a way which allows the experience to be shared for the purposes of understanding the drug discovery and development process. It is the objective of this review to describe the pivotal events and explain why critical decisions were made that resulted in the first therapeutic to successfully target tyrosine kinases in cancer. New approaches and future prospects for therapeutics targeting the HER family are also discussed.


Breast Cancer Serum Pharmacokinetic Disseminate Peritoneal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M 1988 Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611PubMedCrossRefGoogle Scholar
  2. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX 2005 Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727PubMedCrossRefGoogle Scholar
  3. Ajani JA, Randolph HJ, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D 2006 An openlabel, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106:1908-1916PubMedCrossRefGoogle Scholar
  4. Aloysius MM, Robins RA, Eremin JM, Eremin O 2006 Vaccination therapy in malignant disease. Surgeon 4:309-320PubMedCrossRefGoogle Scholar
  5. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B 2006 Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267PubMedCrossRefGoogle Scholar
  6. Ashrafian H 2006 Cancer’s sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. Lancet 367:618-621PubMedCrossRefGoogle Scholar
  7. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G 2004 Alpha-particle emitting atomic generator (Actinium-225)labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 10:4489-4497PubMedCrossRefGoogle Scholar
  8. Baselga J 2001 Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37 Suppl 1:18-24CrossRefGoogle Scholar
  9. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J 1998 Recombinant humanized antiHER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831PubMedGoogle Scholar
  10. Baselga J, Perez EA, Pienkowski T, Bell R 2006 Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl 1:4-12Google Scholar
  11. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L 1996 Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744PubMedGoogle Scholar
  12. Berezov A, Greene MI, Murali R 2003 Structure-based approaches to inhibition of erbB receptors with peptide mimetics. Immunol Res 27:303-308PubMedCrossRefGoogle Scholar
  13. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M, Vezzosi V, Alimandi M, Mariani-Costantini R, Ottini L 2006 ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 206: 702-708PubMedCrossRefGoogle Scholar
  14. Bishop JM (1989) Nobel Prize Lecture: Retroviruses and Oncogenes IIGoogle Scholar
  15. Blumenthal RD, Sharkey RM, Goldenberg DM 1990 Current perspectives and challenges in the use of monoclonal antibodies as imaging and theraputic agents. Adv Drug Deliv Rev 4:279-318CrossRefGoogle Scholar
  16. Brechbiel MW, Waldmann TA 2000 Anti-HER2 radioimmunotherapy. Breast Dis 11:125-132PubMedGoogle Scholar
  17. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S 2003 An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552PubMedCrossRefGoogle Scholar
  18. Carter P, Fendly BM, Lewis GD, Sliwkowski MX 2000 Development of herceptin. Breast Dis 11:103-111PubMedGoogle Scholar
  19. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289PubMedCrossRefGoogle Scholar
  20. Chazin VR, Kaleko M, Miller AD, Slamon DJ 1992 Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859-1866PubMedGoogle Scholar
  21. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS 2001 Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957-1962PubMedGoogle Scholar
  22. Citri A, Yarden Y 2006 EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516PubMedCrossRefGoogle Scholar
  23. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648PubMedGoogle Scholar
  24. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K 1996 The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 271:30897-30903PubMedCrossRefGoogle Scholar
  25. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U 1985 Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139PubMedCrossRefGoogle Scholar
  26. Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE 2005 Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem 16:1117-1125PubMedCrossRefGoogle Scholar
  27. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O 1992 Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 52:1916-1923PubMedGoogle Scholar
  28. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM 1999 The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 96:10869-10874PubMedCrossRefGoogle Scholar
  29. Dorr RT, Von Hoff DD 1994 Cancer Chemotherapy Handbook., 2nd edn. Appleton and Lange, Norwalk, pp 500-515Google Scholar
  30. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI 1985 Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697-706PubMedCrossRefGoogle Scholar
  31. Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A 1990a The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 9:449-455Google Scholar
  32. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A 1990b Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558Google Scholar
  33. Ferrara N 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611PubMedCrossRefGoogle Scholar
  34. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y 2005 Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102:1915-1920PubMedCrossRefGoogle Scholar
  35. Garratt AN 2006 “To erb-B or not to erb-B. . . ” Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol 41:215-218PubMedCrossRefGoogle Scholar
  36. Ghatak S, Misra S, Toole BP 2005 Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280:8875-8883PubMedCrossRefGoogle Scholar
  37. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J 1984 Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755-7760PubMedGoogle Scholar
  38. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM 1989 Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339:155-156PubMedCrossRefGoogle Scholar
  39. Goldenberg DM 1991 Challenges to the therapy of cancer with monoclonal antibodies. J Natl Cancer Inst 83:78-79PubMedCrossRefGoogle Scholar
  40. Goldenberg DM, Sharkey RM 2006 Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imag 50:248-264Google Scholar
  41. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, BorgmannWinter KE, Siegel SJ, Gallop RJ, Arnold SE 2006 Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12:824-828PubMedCrossRefGoogle Scholar
  42. Hall D, Gogos JA, Karayiorgou M 2004 The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 3:240-248PubMedCrossRefGoogle Scholar
  43. Heidelberger C, Chaudhuri Nk, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer Rj, Pleven E, Scheiner J 1957 Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666PubMedCrossRefGoogle Scholar
  44. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD 1992 Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210PubMedCrossRefGoogle Scholar
  45. Hommelgaard AM, Lerdrup M, van DB 2004 Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567PubMedCrossRefGoogle Scholar
  46. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M 2005 Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719PubMedCrossRefGoogle Scholar
  47. Hudziak RM, Lewis GD, Holmes WE, Ullrich A, Shepard HM 1990 Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha. Cell Growth Differ 1:129-134PubMedGoogle Scholar
  48. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM 1988 Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci USA 85:5102-5106PubMedCrossRefGoogle Scholar
  49. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A 1989 p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172PubMedGoogle Scholar
  50. Hudziak RM, Schlessinger J, Ullrich A 1987 Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163PubMedCrossRefGoogle Scholar
  51. Hynes NE, Lane HA 2005 ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354PubMedCrossRefGoogle Scholar
  52. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N 2001 Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84:1377-1383PubMedCrossRefGoogle Scholar
  53. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820PubMedCrossRefGoogle Scholar
  54. Katoh M, Yazaki Y, Sugimura T, Terada M 1993 c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem Biophys Res Commun 192:1189-1197PubMedCrossRefGoogle Scholar
  55. King CR, Kraus MH, Aaronson SA 1985 Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976PubMedCrossRefGoogle Scholar
  56. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639PubMedCrossRefGoogle Scholar
  57. Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM 1996 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm 11:133-144PubMedCrossRefGoogle Scholar
  58. Kris RM, Lax I, Gullick W, Waterfield MD, Ullrich A, Fridkin M, Schlessinger J 1985 Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell 40:619-625PubMedCrossRefGoogle Scholar
  59. Kumar PS, Pegram M 2006 Targeting HER2 Epitopes. Semin Oncol 33:386-391CrossRefGoogle Scholar
  60. Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M 2001 Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 61:179-189PubMedCrossRefGoogle Scholar
  61. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N 1987 Macrophageinduced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329:630-632PubMedCrossRefGoogle Scholar
  62. Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM 1987 Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma. Cancer Res 47:5382-5385PubMedGoogle Scholar
  63. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM 1993 Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263PubMedCrossRefGoogle Scholar
  64. Leyland-Jones B 2001 Dose scheduling-Herceptin. Oncology 61 Suppl 2:31-36Google Scholar
  65. Li Q, Boyer C, Lee JY, Shepard HM 2001 A novel approach to thymidylate synthase as a target for cancer chemotherapy. Mol Pharmacol 59:446-452PubMedGoogle Scholar
  66. Makhija, Glenn D, Ueland F, Gold M, Dizon D, Paton V, Birkner M, Lin C, Derynck M, Matulonis U 2007 Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 25:5507Google Scholar
  67. Maneval DC, Baughman S, Hutchins B, Mordenti J 1991a Pharmacokinetics of MuMab4D5 in cynomolgus monkeys. Pharm Res 8:54Google Scholar
  68. Maneval DC, Hutchins B, Osaka G, Leddy C, Kotts C, Mohler M, Lewis D, Hansen S, Terrell T, Dodd T, Beaumier P, Giltinan D, Shalaby R, Stagg R, Mordenti J, Green J, Fritzberg A, Su FM 1993 Studies with a radiolabeled humanized anti-p185HER2 monoclonal antibody (rhuMab HER2) in tumor-bearing mice. Antibody Immunoconjugates and Radiopharmaceuticals 6:80Google Scholar
  69. Maneval DC, Hutchins B, Osaka G, Leddy C, Kotts C, Vetterlein D, Dodd T, Axworthy D, Beaumeier P, Vanderheyden JL, Shalaby R, Shepard HM, Mordenti J, Fritzberg A, Su FM 1992 Comparative evaluation of I-125 and Re-186 labeled murine anti-p185HER2 antibody (muMAb 4D5) in an animal tumor model. J Nucl Med 33:934Google Scholar
  70. Maneval DC, Mordenti J, Hutchins B, Scates S, Hansen S, Keith D, Kotts C, Fletcher B, Fendly B, Blank G, Vetterlein D, Slamon D, Shepard HM, Green JD 1991b Pharmacokinetics and whole body autoradiography of I-125 muMAb 4D5 in mice. J Nucl Med 32:1837Google Scholar
  71. Maneval DC, Thomas D, Mordenti J, Green J 1991c Utilization of interspecies scaling techniques to support dose selection in the development of a monoclonal antibody in GN 1445. The Toxicologist 11:235Google Scholar
  72. Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M, nilkovitch-Miagkova A 2004 Development and validation of ELISA for herceptin detection in human serum. J Immunol Methods 295:169-182PubMedCrossRefGoogle Scholar
  73. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O’Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274PubMedCrossRefGoogle Scholar
  74. Meeks TW, Ropacki SA, Jeste DV 2006 The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiat 19:581-586CrossRefGoogle Scholar
  75. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW 2005 Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20:557-568PubMedCrossRefGoogle Scholar
  76. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW 2004 Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10:7834-7841PubMedCrossRefGoogle Scholar
  77. Mitchell MS 2003 Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52:686-692PubMedCrossRefGoogle Scholar
  78. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P 1988 Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115PubMedCrossRefGoogle Scholar
  79. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS, III 2006 The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 17:4118-4129PubMedCrossRefGoogle Scholar
  80. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ 2006 Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280PubMedCrossRefGoogle Scholar
  81. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ 2005 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128PubMedCrossRefGoogle Scholar
  82. Nash PT, Florin TH 2005 Tumour necrosis factor inhibitors. Med J Aust 183:205-208PubMedGoogle Scholar
  83. Nawa H, Takei N 2006 Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56:2-13PubMedCrossRefGoogle Scholar
  84. Nelson MH, Dolder CR 2006 Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261-269PubMedCrossRefGoogle Scholar
  85. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM 2005 Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907-5916PubMedCrossRefGoogle Scholar
  86. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O’Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS 2004 Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143PubMedCrossRefGoogle Scholar
  87. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM 1992 Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res 61:193-211PubMedGoogle Scholar
  88. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ 1997 The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547PubMedCrossRefGoogle Scholar
  89. Pegram MD, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251PubMedCrossRefGoogle Scholar
  90. Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ 2004 Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749PubMedCrossRefGoogle Scholar
  91. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671PubMedGoogle Scholar
  92. Perik PJ, Lub-De Hooge MN, Gietema JA, Van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, Van Veldhuisen DJ, Sleijfer DT, Jager PL, De Vries EG 2006 Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282PubMedCrossRefGoogle Scholar
  93. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V 2006 Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 15:673-680PubMedGoogle Scholar
  94. Persson MI, Tolmachev V, Andersson K, Gedda L, Sandstrom M, Carlsson J 2005 [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 32:1457-1462PubMedCrossRefGoogle Scholar
  95. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672PubMedCrossRefGoogle Scholar
  96. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ 1994 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838PubMedGoogle Scholar
  97. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ 1998 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249PubMedCrossRefGoogle Scholar
  98. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y 1996 Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467PubMedGoogle Scholar
  99. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A 2001 The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31PubMedCrossRefGoogle Scholar
  100. Qian X, O’Rourke DM, Zhao H, Greene MI 1996 Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 13:2149-2157PubMedGoogle Scholar
  101. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792PubMedCrossRefGoogle Scholar
  102. Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K 2006 Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 7:254-261PubMedCrossRefGoogle Scholar
  103. Rohrbach S, Niemann B, Silber RE, Holtz J 2005 Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 100:240-249PubMedCrossRefGoogle Scholar
  104. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684PubMedCrossRefGoogle Scholar
  105. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L 1985 The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978PubMedCrossRefGoogle Scholar
  106. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA 1984 The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516PubMedCrossRefGoogle Scholar
  107. Semba K, Kamata N, Toyoshima K, Yamamoto T 1985 A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501PubMedCrossRefGoogle Scholar
  108. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM 2007 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441PubMedCrossRefGoogle Scholar
  109. Shak S 1999 Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26:71-77PubMedGoogle Scholar
  110. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Jr., Ullrich A 1991 Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117-127PubMedCrossRefGoogle Scholar
  111. Shih C, Padhy LC, Murray M, Weinberg RA 1981 Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264PubMedCrossRefGoogle Scholar
  112. Slamon D, Pegram M 2001 Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19PubMedCrossRefGoogle Scholar
  113. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182PubMedCrossRefGoogle Scholar
  114. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712PubMedCrossRefGoogle Scholar
  115. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792PubMedCrossRefGoogle Scholar
  116. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM 2004 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701-706PubMedCrossRefGoogle Scholar
  117. Sosman JA, Sondak VK 2003 Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2:353-368PubMedCrossRefGoogle Scholar
  118. Sporn MB, Todaro GJ 1980 Autocrine secretion and malignant transformation of cells. N Engl J Med 303:878-880PubMedGoogle Scholar
  119. Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM 1987 Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res 47:780-786PubMedGoogle Scholar
  120. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T 1996 In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73:1362-1365PubMedGoogle Scholar
  121. Urban JL, Schreiber H 1988 Host-tumor interactions in immunosurveillance against cancer. Prog Exp Tumor Res 32:17-68PubMedGoogle Scholar
  122. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H 1986 Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83:5233-5237PubMedCrossRefGoogle Scholar
  123. Varmus HE (1989) Nobel Prize Lecture: Retroviruses and Oncogenes I.Google Scholar
  124. Vidal GA, Naresh A, Marrero L, Jones FE 2005 Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 280:19777-19783PubMedCrossRefGoogle Scholar
  125. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726PubMedCrossRefGoogle Scholar
  126. Wang Y, Kristensen GB, Helland A, Nesland JM, Borresen-Dale AL, Holm R 2005 Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124:392-401PubMedCrossRefGoogle Scholar
  127. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI 1989 A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230-231PubMedCrossRefGoogle Scholar
  128. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG 2005 Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:1770-1777PubMedCrossRefGoogle Scholar
  129. Witkop B 1999 Paul Ehrlich and his Magic bullets-revisited. Proc Am Philos Soc 143:540-557PubMedGoogle Scholar
  130. Yarden Y, Sliwkowski MX 2001 Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137PubMedCrossRefGoogle Scholar
  131. Yarden Y, Ullrich A 1988 Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478PubMedCrossRefGoogle Scholar
  132. Yeon CH, Pegram MD 2005 Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23:391-409PubMedCrossRefGoogle Scholar
  133. Zanazzi G, Einheber S, Westreich R, Hannocks MJ, Bedell-Hogan D, Marchionni MA, Salzer JL 2001 Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol 152:1289-1299PubMedCrossRefGoogle Scholar
  134. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK 1996 Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271:3884-3890PubMedCrossRefGoogle Scholar
  135. Zhou W, Carpenter G 2002 ErbB-4: a receptor tyrosine kinase. Inflamm Res 51:91-101PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • H. M. Shepard
    • 1
  • P. Jin
    • 1
  • D. J. Slamon
    • 2
  • Z. Pirot
    • 1
  • D. C. Maneval
    • 1
  1. 1.Receptor BioLogix, Inc.Palo AltoUSA
  2. 2.Division of Hematology and OncologyUniversity of California Los Angeles School of MedicineLos AngelesUSA

Personalised recommendations